Chemical Property of Dosulepin hydrochloride
Chemical Property:
- Appearance/Colour:Crystalline powder
- Vapor Pressure:8.68E-09mmHg at 25°C
- Melting Point:218-221ºC
- Boiling Point:430.9 °C at 760 mmHg
- Flash Point:214.4 °C
- PSA：28.54000
- LogP:5.47770
- Storage Temp.:?20°C
- Solubility.:Freely soluble in water, in alcohol and in methylene chloride.
- Hydrogen Bond Donor Count:1
- Hydrogen Bond Acceptor Count:2
- Rotatable Bond Count:3
- Exact Mass:331.1161486
- Heavy Atom Count:22
- Complexity:363
- Purity/Quality:
-
99%, *data from raw suppliers
DothiepinHydrochloride *data from reagent suppliers
Safty Information:
- Pictogram(s):
F,T,Xn
- Hazard Codes:F,T,Xn
- Statements:
11-23/24/25-39/23/24/25-22
- Safety Statements:
7-16-36/37-45
- MSDS Files:
-
SDS file from LookChem
Useful:
- Canonical SMILES:CN(C)CCC=C1C2=CC=CC=C2CSC3=CC=CC=C31.Cl
- Isomeric SMILES:CN(C)CC/C=C\1/C2=CC=CC=C2CSC3=CC=CC=C31.Cl
- Recent EU Clinical Trials:Establish limits for fitness to drive with prolonged use of ICADTS class III medication
-
Uses
Dothiepin Hydrochloride is a tricyclic antidepressant. Monoamine reuptake inhibitor; tricyclic antidepressant
-
Drug interactions
Potentially hazardous interactions with other drugsAlcohol: increased sedative effect.Analgesics: increased risk of CNS toxicity with
tramadol; possibly increased risk of side effects with
nefopam; possibly increased sedative effects with
opioids.Anti-arrhythmics: increased risk of ventricular
arrhythmias with amiodarone - avoid; increased
risk of ventricular arrhythmias with disopyramide,
dronedarone, flecainide or propafenone - avoid with
dronedarone.Antibacterials: increased risk of ventricular
arrhythmias with moxifloxacin and possibly
delamanid and telithromycin - avoid with
moxifloxacin.Anticoagulants: may alter anticoagulant effect of
coumarins.Antidepressants: enhanced CNS excitation and
hypertension with MAOIs and moclobemide -
avoid; concentration possibly increased with SSRIs;
risk of ventricular arrhythmias with citalopram
and escitalopram - avoid; possible increased risk of
convulsions with vortioxetine.Antiepileptics: convulsive threshold lowered;
concentration reduced by carbamazepine,
phenobarbital and possibly fosphenytoin, phenytoin
and primidone.Antimalarials: avoid with artemether/lumefantrine
and piperaquine with artenimol.Antipsychotics: increased risk of ventricular
arrhythmias especially with droperidol, fluphenazine,
haloperidol, pimozide, risperidone, sulpiride and
zuclopenthixol - avoid; increased antimuscarinic
effects with clozapine and phenothiazines;
concentration increased by antipsychoticsAntivirals: increased risk of ventricular arrhythmias
with saquinavir - avoid; concentration possibly
increased with ritonavir.Atomoxetine: increased risk of ventricular
arrhythmias and possibly convulsions.Beta-blockers: increased risk of ventricular
arrhythmias with sotalol.Clonidine: tricyclics antagonise hypotensive
effect; increased risk of hypertension on clonidine
withdrawal.Dapoxetine: possible increased risk of serotonergic
effects - avoidDopaminergics: avoid use with entacapone; CNS
toxicity reported with selegiline and rasagiline.
